Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesGilles Montalescot, Petr Widimský, Leonardo Bolognese et al.|New England Journal of Medicine|2013Cited by 651
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary SyndromesDominick J. Angiolillo, Mark B. Effron, Jorge F. Saucedo et al.|Journal of the American College of Cardiology|2010Cited by 168
Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registryRichard Beale, Konrad Reinhart, Jonathan Janes et al.|Critical Care|2010Cited by 84
Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.Sara M. Tolaney, Carey K. Anders, P. Kellie Turner et al.|Journal of Clinical Oncology|2017Cited by 53
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrelAndrew L. Frelinger, Eugene Braunwald, Alan D. Michelson et al.|Thrombosis and Haemostasis|2011Cited by 46